Evidence map›Paper›PMID 39881558›Full record

ArticleHepatic oncology2024

APT imaging of hepatocellular carcinoma signals an effective therapeutic response in advance of tumor shrinkage.

Xiaojing Wang, Keisuke Ishimatsu, Junjie Li, Xiaodong Wen, Weijun Ou, Arnida Anwar, Jaideep Chaudhary, Masaya Takahashi, A Dean Sherry, Ian R Corbin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatic oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaojing WangAdvanced Imaging Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.
Keisuke IshimatsuAdvanced Imaging Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.
Junjie LiAdvanced Imaging Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.
Xiaodong WenAdvanced Imaging Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.
Weijun OuAdvanced Imaging Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.
Arnida AnwarAdvanced Imaging Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.
Jaideep ChaudharyAdvanced Imaging Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.
Masaya TakahashiAdvanced Imaging Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.
A Dean SherryAdvanced Imaging Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.
Ian R CorbinAdvanced Imaging Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.ORCID 0000-0001-6902-8034

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7M
UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
UT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI JAY D. HORTON · 2022 to 2026
$7.4M
Image Guided Delivery and Evaluation of Low-Density Lipoprotein- Docosahexaenoic acid Nanoparticles for the Management of Hepatocellular Carcinoma -Diversity SupplementR01CA215702 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI CORBIN, IAN RONALD · 2017 to 2021
$1.9M
Docosahexaenoic Acid Loaded Low-density Lipoproteins: A Novel Biologic Intervention for Hepatocellular Carcinoma.R01CA271496 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Ian Ronald Corbin · 2023 to 2026
$1.8M
NCATS NIH HHS UL1 TR001105NCI NIH HHS P30 CA142543NCI NIH HHS R01 CA215702NCI NIH HHS R01CA215702NCI NIH HHS R01 CA271496NIDDK NIH HHS P30 DK127984Remeditex Ventures LCC OTD-109946
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

docosahexaenoic acidhepatocellular carcinomalow-density lipoproteinmolecular imagingnanoparticle

Identifiers

PMID39881558
PMCPMC11407511

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.